MARKET

OTLC

OTLC

Oncotelic Therapeutics Inc
OTCMQB
0.035
NaN%
Closed 09:30 06/24 EDT
OPEN
--
PREV CLOSE
0.034
HIGH
--
LOW
--
VOLUME
--
TURNOVER
--
52 WEEK HIGH
0.338
52 WEEK LOW
0.019
MARKET CAP
13.99M
P/E (TTM)
-1.7857
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at OTLC last week (0617-0621)?
Weekly Report · 11h ago
Weekly Report: what happened at OTLC last week (0610-0614)?
Weekly Report · 06/17 11:48
ONCOTELIC TO PRESENT AT THE 20TH ANNUAL CONGRESS OF INTERNATIONAL DRUG DISCOVERY SCIENCE & TECHNOLOGY
Barchart · 06/11 07:10
Weekly Report: what happened at OTLC last week (0603-0607)?
Weekly Report · 06/10 11:51
Weekly Report: what happened at OTLC last week (0527-0531)?
Weekly Report · 06/03 11:54
ONCOTELIC TO PARTICIPATE AT THE BIO INTERNATIONAL 2024 MEETING
Oncotelic Therapeutics, Inc will be participating at the BIO International 2024 meeting on June3-6, San Diego. The BIO is the largest and most comprehensive event for biotechnology. More than 18,500 industry leaders from across the globe will attend.
Barchart · 05/30 08:55
Weekly Report: what happened at OTLC last week (0520-0524)?
Weekly Report · 05/27 12:00
Weekly Report: what happened at OTLC last week (0513-0517)?
Weekly Report · 05/20 11:51
More
About OTLC
Oncotelic Therapeutics, Inc., formerly Mateon Therapeutics, Inc., is an immuno-oncology company. The Company is engaged in development of ribonucleic acid (RNA) therapeutics as well as small molecule drugs against cancer and infectious diseases. The Company’s pipeline includes ArtiVeda/ArtiShield, OT-101, CA4P and Oxi4503. The ArtiVeda/ArtiShield is a derivative from the plant Artemisia. Its immuno-oncology drug candidate, OT-101, is developed for the treatment of solid tumors with focus on brain cancer in adult and diffuse intrinsic pontine glioma (DIPG) in children. The Company’s OT-101 completed phase II for pancreatic cancer, melanoma, and glioblastoma. Its CA4P is a vascular disrupting agent (VDA) in combination with Ipilimumab for the treatment of solid tumors with focus on melanoma in adult and pediatric melanoma. The OXi4503 is developed for the treatment of liquid tumors with focus on childhood leukemia.

Webull offers Oncotelic Therapeutics Inc stock information, including OTCMQB: OTLC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OTLC stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading OTLC stock methods without spending real money on the virtual paper trading platform.